Inovio Pharmaceuticals (INO) Stock
What Inovio Pharmaceuticals's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -3.60x
- Revenue growth
- -100.0%
- Debt / equity
- 0.00x
What Inovio Pharmaceuticals's price implies
Inovio Pharmaceuticals's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Inovio Pharmaceuticals's 10-K filings.
Inovio Pharmaceuticals revenue and free cash flow
FY2016–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2M | $10M | $832,010 | $217,756 | $65,343 |
| Net income | -$304M | -$280M | -$135M | -$107M | -$85M |
| Free cash flow | -$217M | -$217M | -$125M | -$105M | -$89M |
| EPS (diluted) | -$17.45 | -$14.07 | -$6.09 | -$3.95 | -$1.81 |
| Operating margin | -16,972.3% | -2,607.4% | -17,300.3% | -51,616.9% | -132,871.3% |
Where the revenue comes from
By products, fiscal 2021. By year
Superinvestors who own INO
From each investor's latest 13F filing (what a 13F shows). All 3 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| David Shaw D. E. Shaw & Co. | Trimmed | $1M | 0.00% | Q2 2026 |
| Two Sigma Two Sigma Investments | Added | $1M | 0.00% | Q2 2026 |
| Jim Simons Renaissance Technologies | Trimmed | $397,473 | 0.00% | Q2 2026 |
Inovio Pharmaceuticals insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of INO in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from INO's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Inovio Pharmaceuticals compares
Inovio Pharmaceuticals's revenue growth is higher than 0% of Healthcare companies and 0% of the 3,491 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 0% | 0% |
| ROE | 0% | 0% |
Questions about Inovio Pharmaceuticals
Are Inovio Pharmaceuticals insiders buying the stock?
No open-market insider purchases of INO in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Inovio Pharmaceuticals?
3 of the superinvestors Investingly tracks hold INO in their latest 13F, including David Shaw, Two Sigma, Jim Simons.
Companies like Inovio Pharmaceuticals
NovaBridge Biosciences (NBP)$102MNRX Pharmaceuticals, Inc. (NRXP)$103MTuHURA Biosciences Inc (HURA)$104MImmunic Inc (IMUX)$106MAnavex Life Sciences Corp (AVXL)$107MCellectis SA (CLLS)$107MFoghorn Therapeutics Inc (FHTX)$110MLENZ Therapeutics Inc (LENZ)$110MAnixa Biosciences Inc (ANIX)$110M All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.